Jordi Mata-Fink, Gate Bioscience CEO
‘Small molecules are sexy again’: Gate Bioscience debuts with $60M and a new way to stop disease-causing proteins
Gate Bioscience has raised $60 million to develop a new type of pill-based medicine — which it calls a molecular gate — that can go after the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
